Src kinase inhibitors induce apoptosis and mediate cell cycle arrest in lymphoma cells

Anti-Cancer Drugs

Volumn 18, Issue 9, 2007, Pages 981-995

  Nowak, Daniel ^a,c   Boehrer, Simone ^a   Hochmuth, Simone ^a   Trepohl, Bettina ^a   Hofmann, Wencke ^a   Hoelzer, Dieter ^a   Hofmann, Wolf Karsten ^a,c   Mitrou, Paris S ^a   Ruthardt, Martin ^a   Chow, Kai Uwe ^a,b  

^a University Hospital   (Germany)

^b Medizinisches Versorgungszentrum   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Apoptosis; Cell cycle; Molecular therapy; Src kinases

Indexed keywords

ABELSON KINASE; ADENOSINE DIPHOSPHATE RIBOSE; AZD 0424; AZD 0530; AZM 559756; BCR ABL PROTEIN; CASPASE; DAXX PROTEIN; FLICE INHIBITORY PROTEIN; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; PROTEIN KINASE LCK; PROTEIN KINASE LYN; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; PROTEINASE ACTIVATED RECEPTOR 4; RETINOBLASTOMA PROTEIN; STEM CELL FACTOR; SURVIVIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CONTROLLED STUDY; DNA CLEAVAGE; DOWN REGULATION; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LYMPHOMA; LYMPHOMA CELL; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAJI CELL; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; DOWN-REGULATION; ENZYME INHIBITORS; HUMANS; LYMPHOMA; NEOPLASM PROTEINS; PHOSPHORYLATION; SRC-FAMILY KINASES;

EID: 34548086185     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3281721ff6     Document Type: Article

References (67)

1. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997; 13:513-609.
2. Bjorge JD, Jakymiw A, Fujita DJ. Selected glimpses into the activation and function of Src kinase. Oncogene 2000; 19:5620-5635.
3. Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene 2000; 19:5636-5642.
4. Martinelli G, Soverini S, Rosti G, Cilloni D, Baccarani M. New tyrosine kinase inhibitors in chronic myeloid leukemia. Haematologica 2005; 90:534-541.
5. Liu Z, Falola J, Zhu X, Gu Y, Kim LT, Sarosi GA, et al. Antiproliferative effects of Src inhibition on medullary thyroid cancer. J Clin Endocrinol Metab 2004; 89:3503-3509.
6. Yezhelyev MV, Koehl G, Guba M, Brabletz T, Jauch KW, Ryan A, et al. Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin Cancer Res 2004; 10: 8028-8036.
7. Lee M, Kim JY, Koh WS. Apoptotic effect of PP2: a Src tyrosine kinase inhibitor, in murine B cell leukemia. J Cell Biochem 2004; 93:629-638.
8. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res 2004; 10: 2307-2318.
9. Boyd DD, Wang H, Avila H, Parikh NU, Kessler H, Magdolen V, et al. Combination of an SRC kinase inhibitor with a novel pharmacological antagonist of the urokinase receptor diminishes in vitro colon cancer invasiveness. Clin Cancer Res 2004; 10:1545-1555.
10. Tatton L, Morley GM, Chopra R, Khwaja A. The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases. J Biol Chem 2003; 278:4847-4853. Epub 2002 Dec 9.
11. Golas JM, Arndt K, Etienne C, Lucas J, Nardin D, Gibbons J, et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 2003; 63:375-381.
12. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305:399-401.
13. Nimmanapalli R, O'Bryan E, Huang M, Bali P, Burnette PK, Loughran T, et al. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Cancer Res 2002; 62:5761-5769.
14. Schriever F, Huhn D. New directions in the diagnosis and treatment of chronic lymphocytic leukaemia. Drugs 2003; 63:953-969.
15. Reed JC. Molecular biology of chronic lymphocytic leukemia. Semin Oncol 1998; 25:11-18.
16. Chow KU, Nowak D, Hofmann W, Schneider B, Hofmann WK. Imatinib induces apoptosis in CLL lymphocytes with high expression of Par-4. Leukemia 2005; 19:1103-1105; author reply 1105-1106; discussion 1106-1107.
17. Aloyz R, Grzywacz K, Xu ZY, Loignon M, Alaoui-Jamali MA, Panasci L. Imatinib sensitizes CLL lymphocytes to chlorambucil. Leukemia 2004; 18:409-414.
18. Contri A, Brunati AM, Trentin L, Cabrelle A, Miorin M, Cesaro L, et al. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest 2005; 115:369-378.
19. Sprangers M, Feldhahn N, Herzog S, Hansmann ML, Reppel M, Hescheler J, et al. The SRC family kinase LYN redirects B cell receptor signaling in human SLP65-deficient B cell lymphoma cells. Oncogene 2006; 25: 5056-5062.
20. Prakash O, Swamy OR, Peng X, Tang ZY, Li L, Larson JE, et al. Activation of Src kinase Lyn by the Kaposi sarcoma-associated herpesvirus K1 protein: implications for lymphomagenesis. Blood 2005; 105: 3987-3994.
21. Hennequin LF, Allen J, Breed J, Curwen J, Fennell M, Green TP, et al. N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy] -5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J Med Chem 2006; 49:6465-6488.
22. Mizenina OA, Moasser MM. S-phase inhibition of cell cycle progression by a novel class of pyridopyrimidine tyrosine kinase inhibitors. Cell Cycle 2004; 3:796-803.
23. Taylor SJ, Shalloway D. Src and the control of cell division. Bioessays 1996; 18:9-11.
24. Lowell CA. Src-family kinases: rheostats of immune cell signaling. Mol Immunol 2004; 41:631-643.
25. Breitschopf K, Zeiher AM, Dimmeler S. Ubiquitin-mediated degradation of the proapoptotic active form of bid. A functional consequence on apoptosis induction. J Biol Chem 2000; 275:21648-21652.
26. Deveraux QL, Reed JC. IAP family proteins - suppressors of apoptosis. Genes Dev 1999; 13:239-252.
27. Boehrer S, Chow KU, Beske F, Kukoc-Zivojnov N, Puccetti E, Ruthardt M, et al. In lymphatic cells par-4 sensitizes to apoptosis by down-regulating bcl-2 and promoting disruption of mitochondrial membrane potential and caspase activation. Cancer Res 2002; 62:1768-1775.
28. Boehrer S, Nowak D, Hochmuth S, Kim SZ, Trepohl B, Afkir A, et al. Daxx overexpression in T-lymphoblastic Jurkat cells enhances caspase-dependent death receptor- and drug-induced apoptosis in distinct ways. Cell Signal 2005; 17:581-595.
29. Boehrer S, Nowak D, Kukoc-Zivojnov N, Hochmuth S, Kim SZ, Hoelzer D, et al. Expression of Daxx sensitizes Jurkat T-cells to the apoptosis-inducing effect of chemotherapeutic agents. Pharmacol Res 2005; 51: 367-374.
30. Brieger A, Boehrer S, Schaaf S, Nowak D, Ruthardt M, Kim SZ, et al. In bcr-abl-positive myeloid cells resistant to conventional chemotherapeutic agents, expression of Par-4 increases sensitivity to imatinib (STI571) and histone deacetylase-inhibitors. Biochem Pharmacol 2004; 68:85-93.
31. Chow KU, Nowak D, Boehrer S, Ruthardt M, Knau A, Hoelzer D, et al. Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation. Biochem Pharmacol 2003; 66:711-724.
32. Kawai T, Akira S, Reed JC. ZIP kinase triggers apoptosis from nuclear PML oncogenic domains. Mol Cell Biol 2003; 23:6174-6186.
33. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002; 2:103-112.
34. Chen R, Kim O, Yang J, Sato K, Eisenmann KM, McCarthy J, et al. Regulation of Akt/PKB activation by tyrosine phosphorylation. J Biol Chem 2001; 276:31858-31862. Epub 2001 Jul 9.
35. Cox AD, Der CJ. The dark side of Ras: regulation of apoptosis. Oncogene 2003; 22:8999-9006.
36. Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer 2002; 2:764-776.
37. Chow KU, Nowak D, Hofmann W, Schneider B, Hofmann WK. Imatinib induces apoptosis in CLL lymphocytes with high expression of Par-4. Leukemia 2005; 19:1103-1105.
38. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. 1997;513-609.
39. Abraham KM, Levin SD, Marth JD, Forbush KA, Perlmutter RM. Delayed thymocyte development induced by augmented expression of p56lck. J Exp Med 1991; 173:1421-1432.
40. Abraham KM, Levin SD, Marth JD, Forbush KA, Perlmutter RM. Thymic tumorigenesis induced by overexpression of p56lck. Proc Natl Acad Sci USA 1991; 88:3977-3981.
41. Abraham N, Miceli MC, Parnes JR, Veillette A. Enhancement of T-cell responsiveness by the lymphocyte-specific tyrosine protein kinase p56lck. Nature 1991; 350:62-66.
42. Huntington ND, Tarlinton DM. CD45: direct and indirect government of immune regulation. Immunol Lett 2004; 94:167-174.
43. Burns CM, Sakaguchi K, Appella E, Ashwell JD. CD45 regulation of tyrosine phosphorylation and enzyme activity of src family kinases. J Biol Chem 1994; 269:13594-13600.
44. D'Oro U, Sakaguchi K, Appella E, Ashwell JD. Mutational analysis of Lck in CD45-negative T cells: dominant role of tyrosine 394 phosphorylation in kinase activity. Mol Cell Biol 1996; 16:4996-5003.
45. D'Oro U, Ashwell JD. Cutting edge: the CD45 tyrosine phosphatase is an inhibitor of Lck activity in thymocytes. J Immunol 1999; 162: 1879-1883.
46. Shrivastava P, Katagiri T, Ogimoto M, Mizuno K, Yakura H. Dynamic regulation of Src-family kinases by CD45 in B cells. Blood 2004; 103:1425-1432. Epub 2003 Oct 16.
47. Altieri DC. Molecular circuits of apoptosis regulation and cell division control: the survivin paradigm. J Cell Biochem 2004; 92: 656-663.
48. Lens SM, Vader G, Medema RH. The case for Survivin as mitotic regulator. Curr Opin Cell Biol 2006; 18:616-622.
49. Cong XL, Han ZC. Survivin and leukemia. Int J Hematol 2004; 80: 232-238.
50. Nowak D, Boehrer S, Brieger A, Kim SZ, Schaaf S, Hoelzer D, et al. Upon drug-induced apoptosis in lymphoma cells X-linked inhibitor of apoptosis (XIAP) translocates from the cytosol to the nucleus. Leuk Lymphoma 2004; 45:1429-1436.
51. Chow KU, Nowak D, Kim SZ, Schneider B, Komor M, Boehrer S, et al. In vivo drug-response in patients with leukemic non-Hodgkin's lymphomas is associated with in vitro chemosensitivity and gene expression profiling. Pharmacol Res 2006; 53:49-61.
52. Boehrer S, Nowak D, Hoelzer D, Mitrou PS, Chow KU. Novel agents aiming at specific molecular targets increase chemosensitivity and overcome chemoresistance in hematopoietic malignancies. Curr Pharm Des 2006; 12:111-128.
53. Delston RB, Harbour JW. Rb at the interface between cell cycle and apoptotic decisions. Curr Mol Med 2006; 6:713-718.
54. Liu H, Dibling B, Spike B, Dirlam A, Macleod K. New roles for the RB tumor suppressor protein. Curr Opin Genet Dev 2004; 14:55-64.
55. Guy M, Moorghen M, Bond JA, Collard TJ, Paraskeva C, Williams AC. Transcriptional down-regulation of the retinoblastoma protein is associated with differentiation and apoptosis in human colorectal epithelial cells. Br J Cancer 2001; 84:520-528.
56. Dou QP, An B. RB and apoptotic cell death. Front Biosci 1998; 3:d419-d430.
57. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005; 9:59-71.
58. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428:332-337.
59. Cowling VH, Cole MD. Mechanism of transcriptional activation by the Myc oncoproteins. Semin Cancer Biol 2006; 16:242-252.
60. Arvanitis C, Felsher DW. Conditional transgenic models define how MYC initiates and maintains tumorigenesis. Semin Cancer Biol 2006; 16:313-317.
61. Dang CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 1999; 19:1-11.
62. Eilers M. Control of cell proliferation by Myc family genes. Mol Cells 1999; 9:1-6.
63. Dominguez-Caceres MA, Garcia-Martinez JM, Calcabrini A, Gonzalez L, Porque PG, Leon J, et al. Prolactin induces c-Myc expression and cell survival through activation of Src/Akt pathway in lymphoid cells. Oncogene 2004; 23:7378-7390.
64. De Alboran IM, O'Hagan RC, Gartner F, Malynn B, Davidson L, Rickert R, et al. Analysis of C-MYC function in normal cells via conditional gene-targeted mutation. Immunity 2001; 14:45-55.
65. Biroccio A, Benassi B, Amodei S, Gabellini C, Del Bufalo D, Zupi G. c-Myc down-regulation increases susceptibility to cisplatin through reactive oxygen species-mediated apoptosis in M14 human melanoma cells. Mol Pharmacol 2001; 60:174-182.
66. Bressin C, Bourgarel-Rey V, Carre M, Pourroy B, Arango D, Braguer D, et al. Decrease in c-Myc activity enhances cancer cell sensitivity to vinblastine. Anticancer Drugs 2006; 17:181-187.
67. Greco C, D'Agnano I, Vitelli G, Vona R, Marino M, Mottolese M, et al. c-MYC deregulation is involved in melphalan resistance of multiple myeloma: role of PDGF-BB. Int J Immunopathol Pharmacol 2006; 19:67-79.